Next Article in Journal
Retraction: X. Ma et al. Hybrid Endovascular Repair in Aortic Arch Pathologies: A Retrospective Study. Int. J. Mol. Sci. 2010, 11, 4687–4696
Next Article in Special Issue
Research Advances on Pathways of Nickel-Induced Apoptosis
Previous Article in Journal
Human Anti-Oxidation Protein A1M—A Potential Kidney Protection Agent in Peptide Receptor Radionuclide Therapy
Previous Article in Special Issue
Transducer of ERBB2.1 (TOB1) as a Tumor Suppressor: A Mechanistic Perspective
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 16
Issue 12
10.3390/ijms161226232
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

FLIP the Switch: Regulation of Apoptosis and Necroptosis by cFLIP

by
Yuichi Tsuchiya
*,
Osamu Nakabayashi
and
Hiroyasu Nakano
Department of Biochemistry, Toho University School of Medicine, Tokyo 143-8540, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2015, 16(12), 30321-30341; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms161226232
Submission received: 10 November 2015 / Revised: 9 December 2015 / Accepted: 11 December 2015 / Published: 18 December 2015
(This article belongs to the Collection Programmed Cell Death and Apoptosis)
Browse Figures
Versions Notes

Abstract

:
cFLIP (cellular FLICE-like inhibitory protein) is structurally related to caspase-8 but lacks proteolytic activity due to multiple amino acid substitutions of catalytically important residues. cFLIP protein is evolutionarily conserved and expressed as three functionally different isoforms in humans (cFLIPL, cFLIPS, and cFLIPR). cFLIP controls not only the classical death receptor-mediated extrinsic apoptosis pathway, but also the non-conventional pattern recognition receptor-dependent apoptotic pathway. In addition, cFLIP regulates the formation of the death receptor-independent apoptotic platform named the ripoptosome. Moreover, recent studies have revealed that cFLIP is also involved in a non-apoptotic cell death pathway known as programmed necrosis or necroptosis. These functions of cFLIP are strictly controlled in an isoform-, concentration- and tissue-specific manner, and the ubiquitin-proteasome system plays an important role in regulating the stability of cFLIP. In this review, we summarize the current scientific findings from biochemical analyses, cell biological studies, mathematical modeling, and gene-manipulated mice models to illustrate the critical role of cFLIP as a switch to determine the destiny of cells among survival, apoptosis, and necroptosis.

1. Introduction

The homeostasis of our tissues, organs, and whole body is maintained by the continuous flow of birth, growth, differentiation, and death of cells. Cell death is therefore the indispensable component of our life, and several sophisticated cell death-inducing machineries are installed in the genomes of multicellular organisms. Apoptosis is the most popular pathway to eliminate unnecessary or harmful cells. In addition, recent scientific advances have revealed that other regulated cell death pathways, including programmed necrosis also known as necroptosis, mitochondrial permeability transition-driven regulated cell death, pyroptosis, and ferroptosis, play important roles in maintaining tissue homeostasis under normal and pathological conditions [1].
One physiological function of apoptosis is to kill and remove virus-infected cells in order to protect the hosts from viral propagation. To escape from the host’s protective machinery, some viruses express anti-apoptotic proteins to prevent the host cells from apoptotic cell death. In 1997, Thome et al. [2] identified viral FLICE-inhibitory proteins (vFLIPs), which contained two death effector domains (DEDs) and interfered with apoptosis signaling through death receptors. As vFLIPs were highly similar to the N-terminus of procaspase-8 (also known as FLICE, MACH or Mch-5), it was assumed that these viral genes might be derived from host genes. As expected, Irmler et al. [3] identified a highly related gene in human genome and named this as CFLAR (CASP8 and FADD-like apoptosis regulator). CFLAR gene is located on human chromosome 2q33-34 adjacent to genes encoding caspase-8 and caspase-10, suggesting that these three genes were generated by ancient gene duplication (Figure 1).
Ijms 16 26232 g001 1024
Figure 1. The structures of gene and proteins for human cFLIP. For gene structure, the red arrow (CFLAR gene) and black arrows (the nearby genes) indicate the positions and directions of genes present on human chromosome 2q33-34. For protein structures, light magenta and light yellow boxes indicate DEDs and caspase-8-like domains, respectively. The numbers below the boxes indicate amino acid residues, and arrows above the boxes indicate the caspase-8-mediated cleavage sites.
Figure 1. The structures of gene and proteins for human cFLIP. For gene structure, the red arrow (CFLAR gene) and black arrows (the nearby genes) indicate the positions and directions of genes present on human chromosome 2q33-34. For protein structures, light magenta and light yellow boxes indicate DEDs and caspase-8-like domains, respectively. The numbers below the boxes indicate amino acid residues, and arrows above the boxes indicate the caspase-8-mediated cleavage sites.
Ijms 16 26232 g001
Human CFLAR gene is composed of 14 exons, and multiple mRNAs are produced via alternative splicing. The protein product of CFLAR gene, named as cellular FLIP or cFLIP, is expressed as three major isoforms in humans. cFLIPL is a 55 kDa protein containing N-terminal two DEDs and C-terminal caspase-like domain. Although this domain organization is highly similar to that of procaspase-8, the catalytically important amino acid residues are not conserved in cFLIPL. Therefore, cFLIPL does not possess caspase-like proteolytic activity by itself. cFLIPS is a 27 kDa protein composed of only two DEDs without caspase-like domain, but is absent in mice due to the lack of corresponding exon in mice genome. These proteins were also independently identified and named as CASH, CASP8AP1, CLARP, Casper, FLAME, FLIP, I-FLICE, MRIT, or usurpin, suggesting that the discovery of cFLIP had a significant impact on the field of cell death research [4,5,6,7,8,9,10]. Another short form protein of 25 kDa, named as cFLIPR, is specifically expressed in some cell lines such as Raji and SKW6.4 and in human primary T cells [11,12]. Ueffing et al. [13] reported that a single nucleotide polymorphism, named as rs10190751, determines whether human CFLAR gene produces cFLIPS or cFLIPR. All isoforms are currently supposed to form heterodimers with caspase-8 via DED–DED interaction. In addition, truncated cFLIP fragments named as p43-FLIP and p22-FLIP are generated by caspase-8-mediated cleavages after Asp376 and Asp196, respectively. The gene encoding cFLIP is evolutionarily conserved in vertebrates [14], and both cFLIPL and cFLIPR are also expressed in mice. Asp376 of human cFLIPL is conserved in mouse cFLIPL (Asp377), whereas Asp196 is only present in human cFLIPL. Therefore, p22-FLIP is produced by caspase-8-mediated cleavage only in humans.
Extensive analyses have revealed that cFLIP controls not only the classical death receptor-mediated extrinsic apoptosis pathway, but also the non-conventional pattern recognition receptor-dependent apoptotic pathway. In addition, cFLIP regulates the formation of death receptor-independent apoptosis platform named as ripoptosome. Moreover, recent finding have also indicated the involvement of cFLIP during another cell death pathway named as necroptosis. Therefore, cFLIP exerts critical functions to determine the cellular fate between survival and death in a highly regulated manner.
In this review, we will focus on three topics of the physiological roles of cFLIP as follows: (1) molecular functions of cFLIP in death receptor-mediated apoptosis pathway, ripoptosome formation, and necroptosis; (2) quantitative regulation of cFLIP by the ubiquitin-proteasome system; and (3) physiological roles of cFLIP to maintain tissue and systemic homeostasis in mammals. We encourage the readers to also refer to our complementary review [15]. The cellular functions as well as transcriptional and post-translational regulation of cFLIP are also extensively reviewed by Safa [16].

2. Molecular Functions of cFLIP in Death Receptor-Mediated Apoptosis Pathway, Ripoptosome Formation, and Necroptosis

2.1. Molecular Function of cFLIP in Death Receptor-Dependent Apoptosis Pathway

The death receptor-mediated extrinsic apoptosis pathway is initiated when the extracellular tumor necrosis factor (TNF) superfamily death ligands including TNF-α, Fas ligand/CD95L, and TNF-related apoptosis-inducing ligand (TRAIL) bind to specific cell surface death receptors. These ligand–receptor interactions induce the oligomerization of receptor subunits, association of adaptor proteins including Fas-associated death domain (FADD) or TNF receptor-associated death domain (TRADD) via the interaction between death domain (DD) of receptors and adaptors. Next, the DED of FADD binds to DED of procaspase-8/10 to form death-inducing signaling complex (DISC). Local concentration of procaspase-8/10 at DISC leads to the formation of procaspase-8/10 homodimer and subsequent self-processing to generate active caspase-8/10. Fully processed active caspase-8/10 is then released from DISC and activates downstream effector caspases. Caspase-10 appears functionally similar to caspase-8, but the absence of caspase-10 in rodents suggests that caspase-8 is the major initiator in extrinsic apoptosis pathway, and we therefore discuss only caspase-8 in this review. As cFLIP is highly similar to procaspase-8 but lacks catalytic activity by itself, one may easily suppose that all cFLIP isoforms inhibit the processing of procaspase-8 through heterodimerization. However, the initial characterization of cFLIP by cellular overexpression studies gave conflicting results with regard to apoptosis regulation [3,4,5,6,7,8,9,10,17,18,19]. Extensive biochemical analysis revealed that cFLIPL was in fact a more potent activator of procaspase-8 than procaspase-8 itself [20], and forced dimerization experiments suggested that cFLIPL was able to activate procaspase-8 without interdomain cleavage and altered its substrate specificity [21]. Yu et al. [22] found that p43-FLIP, generated by procaspase-8-mediated cleavage, showed enhanced heterodimerization with procaspase-8 than noncleaved cFLIPL. Therefore, cFLIPL-mediated caspase-8 regulation is more complex than initially suggested. In contrast, it is believed that both cFLIPS and cFLIPR simply block procaspase-8 activation through heterodimerization.
Recent technical advances of quantitative mass spectrometric analysis enabled us to estimate not only the presence, but also the amount of molecules in a given protein complex. Using this technique, Dickens et al. [23] estimated the stoichiometry of TRAIL-induced DISC, whereas Schleich et al. [24] analyzed the stoichiometry of CD95L-induced DISC. Both researchers found that DISC contained several-fold more procaspase-8 than FADD, and that the amount of cFLIP in native DISC was very low. These results suggested that multiple procaspase-8 molecules could bind to single FADD molecule or cFLIP. Previous studies indicated that DEDs from procaspase-8, FADD, and cFLIP formed filament-like structure known as “death-effector filaments” when overexpressed in cells [25], suggesting that procaspase-8 in DISC might form chain-like structure through DED–DED interaction. In contrast, Majkut et al. [26] carried out quantitative Western blotting to find that the ratio of (procaspase-8 + cFLIP):FADD in DR5 agonistic antibody-induced DISC was 2:1 at most, arguing against the DED chain model. However, the stoichiometry may be dependent on cell types, death receptor-death ligand specificities, and the strength of death signals. Majkut et al. [26] further combined site-directed mutagenesis and molecular modeling to propose a two-step DISC model. According to their model, homodimerization of procaspase-8 at DISC produces fully processed caspase-8 and efficiently induces apoptosis. cFLIPL incorporated in the chain can form heterodimer with procaspase-8 and activate it in the absence of interdomain processing. However, cFLIPL-activated procaspase-8 is bound to DISC via DED-DED interaction, and cleaves only limited substrates around DISC. This model may explain why cFLIPL can inhibit apoptosis while possessing the biochemical ability to activate procaspase-8. Kallenberger et al. [27] also used cell compartment-specific fluorescent probes to establish a mathematical model of procaspase-8 activation kinetics. They concluded that procaspase-8 was first cleaved at prodomain in an intra-dimeric manner within a single DISC. Subsequently, the association of multiple DISCs induced the cleavage of procaspase-8 at enzymatic domain in an inter-dimeric manner, followed by the cytoplasmic release of fully processed caspase-8. In contrast, cFLIPS and cFLIPR incorporated in the chain bind to but cannot activate procaspase-8. Similarly, Schleich et al. [28] very recently reported that the N-terminal prodomain of procaspase-8, generated by the complete processing of procaspase-8 and structurally related to cFLIPS/R, remained in DISC and constituted a negative feedback loop to terminate procaspase-8 activation. These short isoforms were initially believed to maintain cell survival by simply inhibiting apoptosis (Figure 2). However, in some situations, the inactive procaspase-8-cFLIPS/R complex can initiate an alternative non-apoptotic cell death program termed as necroptosis, which will be described below.
Ijms 16 26232 g002 1024
Figure 2. Functional role of cFLIP during classical death receptor-mediated extrinsic apoptosis pathway. Upon stimulation by death ligand (gray), death receptor (white) forms trimer and activated. Adaptor protein FADD (green) then binds to activated death receptor via DD-DD interaction. Subsequently, DED-containing proteins including procaspase-8 (blue), cFLIPL (red), and cFLIPS (orange) are recruited to death receptor-bound FADD via DED-DED interaction, thereby forming DISC. Fully processed active caspase-8, generated by procaspase-8 homodimerization, activates effector caspases and induces apoptosis. Procaspase-8-cFLIPL heterodimerization results in the production of p43-FLIP and p22-FLIP but does not process procaspase-8, leading to cellular survival. In contrast, procaspase-8-cFLIPS heterodimerization inhibits the activation of procaspase-8 and prevents apoptosis.
Figure 2. Functional role of cFLIP during classical death receptor-mediated extrinsic apoptosis pathway. Upon stimulation by death ligand (gray), death receptor (white) forms trimer and activated. Adaptor protein FADD (green) then binds to activated death receptor via DD-DD interaction. Subsequently, DED-containing proteins including procaspase-8 (blue), cFLIPL (red), and cFLIPS (orange) are recruited to death receptor-bound FADD via DED-DED interaction, thereby forming DISC. Fully processed active caspase-8, generated by procaspase-8 homodimerization, activates effector caspases and induces apoptosis. Procaspase-8-cFLIPL heterodimerization results in the production of p43-FLIP and p22-FLIP but does not process procaspase-8, leading to cellular survival. In contrast, procaspase-8-cFLIPS heterodimerization inhibits the activation of procaspase-8 and prevents apoptosis.
Ijms 16 26232 g002

2.2. Molecular Function of cFLIP in Ripoptosome Formation and Necroptosis

Under specific conditions, cells can activate caspase-8 in the absence of extrinsic death ligand–death receptor interactions. Receptor interacting protein kinase 1 (RIPK1), also known as RIP1, was originally identified as a protein which interacted with TNF receptor 1 signaling complex [29,30]. Recent explosive scientific advances have revealed the critical roles of RIPK1 in cell fate regulation among survival, apoptosis, and necroptosis. RIPK1 itself is also functionally regulated through phosphorylation and ubiquitylation. Cellular inhibitors of apoptosis proteins (cIAPs) are E3 ubiquitin ligases known to ubiquitylate RIPK1 as well as themselves [31]. To examine whether the elimination of cIAPs via self-ubiquitylation and proteasome-mediated degradation could affect cell death programs, Tenev et al. [32] used a cytotoxic drug etoposide to induce genotoxic stress-induced cell death. Feoktistova et al. [33] employed an IAP antagonist, also known as Smac mimetic, in combination with dsRNA poly I:C to induce Toll-like receptor 3 (TLR3)-mediated cell death. Both authors observed the spontaneous, death receptor-independent formation of ripoptosome, a 2 MDa complex containing RIPK1, FADD, caspase-8 and cFLIP (Figure 3).
Ijms 16 26232 g003 1024
Figure 3. Functional role of cFLIP during ripoptosome formation. RIPK1 (brown) is composed of catalytic kinase domain, RIP homotypic interaction motif (RHIM), and DD. Upon RIPK1 activation by genotoxic stress, DD of RIPK1 is exposed and binds to DD of FADD (green). Subsequently, DED-containing proteins including procaspase-8 (blue), cFLIPL (red), and cFLIPS (orange) are recruited to RIPK1-bound FADD via DED-DED interaction, thereby forming ripoptosome. Fully processed active caspase-8, generated by procaspase-8 homodimerization, activates effector caspases, cleaves RIPK1, disassembles ripoptosome, and induces apoptosis. Procaspase-8-cFLIPL heterodimer produces p43-FLIP and p22-FLIP, cleaves RIPK1, disassembles ripoptosome, but does not process procaspase-8, leading to cellular survival. In contrast, procaspase-8-cFLIPS heterodimer fails to cleave RIPK1. This leads to the assembly of necrosome composed of RIPK1-RIPK3-MLKL and the execution of necroptosis.
Figure 3. Functional role of cFLIP during ripoptosome formation. RIPK1 (brown) is composed of catalytic kinase domain, RIP homotypic interaction motif (RHIM), and DD. Upon RIPK1 activation by genotoxic stress, DD of RIPK1 is exposed and binds to DD of FADD (green). Subsequently, DED-containing proteins including procaspase-8 (blue), cFLIPL (red), and cFLIPS (orange) are recruited to RIPK1-bound FADD via DED-DED interaction, thereby forming ripoptosome. Fully processed active caspase-8, generated by procaspase-8 homodimerization, activates effector caspases, cleaves RIPK1, disassembles ripoptosome, and induces apoptosis. Procaspase-8-cFLIPL heterodimer produces p43-FLIP and p22-FLIP, cleaves RIPK1, disassembles ripoptosome, but does not process procaspase-8, leading to cellular survival. In contrast, procaspase-8-cFLIPS heterodimer fails to cleave RIPK1. This leads to the assembly of necrosome composed of RIPK1-RIPK3-MLKL and the execution of necroptosis.
Ijms 16 26232 g003
According to the currently proposed model [34], procaspase-8 incorporated in ripoptosome is activated and fully processed through homodimerization, cleaves and inactivates RIPK1, and disassembles ripoptosome. As a consequence, only caspase-8-mediated apoptosis is executed. When cFLIPL is incorporated in ripoptosome, it activates procaspase-8 through heterodimerization. However, cFLIPL-activated procaspase-8 is able to cleave limited substrates and inactivate RIPK1, but becomes inactive again after ripoptosome disassembly. As a consequence, cFLIPL blocks apoptosis and maintains cell survival.
In contrast, cFLIPS promotes ripoptosome assembly but cannot activate procaspase-8 to inactivate RIPK1. Under these conditions, cells undergo another type of cell death known as necroptosis. Necroptosis is clearly distinct from accidental necrosis, as it is physiologically regulated by specific proteins including RIPK1, receptor-interacting protein kinase 3 (RIPK3, also known as RIP3), and mixed lineage kinase-like protein (MLKL). These proteins are the main components of necroptosis-inducing complex known as necrosome. In the current scenario, RIPK1 phosphorylates and activates RIPK3, and activated RIPK3 then phosphorylates MLKL. Phosphorylated MLKL forms oligomer via N-terminal four helix bundles domain, translocates to plasma membrane, and induces necrotic cell death by forming pores on the plasma membrane [35]. The activation of necroptosis pathway requires the presence of functional RIPK1-RIPK3-MLKL axis, as He et al. [36] reported that several cell lines lacking RIPK3 expression were resistant to necroptosis. Feoktistova et al. [37] also reported that necroptosis promoted by the elimination of IAPs and the overexpression of MC159 vFLIP was dependent on the kinase activity of RIPK3. Inhibition of RIPK3 kinase activity by either chemical compounds or active site D161N mutation (but not other inactive mutants) blocked necroptosis, but unexpectedly induced apoptosis via the formation of ripoptosome-like platform. Unlike TNF-α-induced apoptosis, RIPK3 inhibitor-induced apoptosis was enhanced by cFLIPL in mouse embryonic fibroblasts [38]. These results indicate that the functional RIPK1-RIPK3-MLKL axis and the balance of cFLIP isoforms are both critical determinants of cell fate switching among survival, apoptosis, and necroptosis. However, it is still not clear whether cFLIPS and vFLIP actively promotes necroptosis execution, or simply fail to inhibit necroptosis due to their inability to block RIPK1-RIPK3-MLKL axis.
cFLIP is also involved in the formation of other death-inducing protein complexes. Day et al. [39] identified an apoptotic inhibitory complex comprised of DR5-, FADD-, Caspase-8-, and cFLIPL.in MCF-7 breast cancer cells. They found that the removal of cFLIPL from this complex resulted in the spontaneous ligand-independent apoptosis, although it was not clear whether RIPK1 was involved in this process. Estornes et al. [40] reported the dsRNA-induced formation of an atypical death complex composed of TLR3, TIR domain-containing adaptor inducing interferon-β (TRIF), and caspase-8. In contrast with ripoptosome, this TLR3-dependent complex required RIPK1 but not FADD to activate procaspase-8. These results suggest that multiple ripoptosome-like apoptosis-inducing complexes can be formed by different death-inducing stimuli.

3. Quantitative Regulation of cFLIP by Ubiquitin-Proteasome System

3.1. cFLIP Concentration as a Critical Parameter for Cell Fate Determination Revealed by Mathematical Modeling

The endogenous concentration of cFLIP in cells is generally low compared to that of procaspase-8. Mathematical modeling studies have revealed that the ratio between procaspase-8 and cFLIP is a critical parameter for cell fate determination by death receptor signaling. Bentele et al. [41] developed a mathematical modeling framework model of CD95L-mediated apoptosis and found that the concentration of cFLIPL determined the threshold ligand concentration. Moreover, Lavrik et al. [42,43] experimentally revealed that the low concentrations of CD95L below the threshold resulted in extracellular signal-regulated kinase (ERK) activation and transduction of survival signaling. Accordingly, cFLIPL could either accelerate or slow down cell death in a CD95L and cFLIPL dose-dependent manner, whereas cFLIPS and cFLIPR only inhibited procaspase-8 activation [44]. Computational simulation by Han et al. [45] also predicted that cFLIPL established bistability in caspase-8 and caspase-3 activation. In addition, Neumann et al. [46] introduced an integrated kinetic mathematical model for CD95L-mediated apoptotic and NF-κB signaling. They concluded that cFLIPL recruitment kinetics to DISC and subsequent generation of p43-FLIP was the critical parameter, and that a subtle balance between cFLIPL and procaspase-8 determined life/death decision in a nonlinear manner. According to their model, the precise quantitative regulation of cFLIP is a critical factor to determine the death ligand sensitivity and cell fate determination. The endogenous expression levels of cFLIP and caspase-8 are highly variable among cell lines, which may explain the different results in the previously published cellular studies [47].

3.2. Regulation of cFLIP Concentration by Proteolysis

The next question is: how is the concentration of cFLIP protein regulated? The amount of a given protein may be regulated transcriptionally, translationally, and post-translationally. Among these, protein degradation is the quickest way to change its concentration. In this section, we specifically focus on the post-translational regulation of cFLIP by proteolysis. All isoforms of cFLIP are reported to be unstable proteins with rapid turnover, and a mathematical modeling study by Toivonen et al. [48] indicated cFLIP turnover as a key determinant of death receptor responses. Previous literatures have suggested that cFLIP is mainly degraded via the ubiquitin-proteasome pathway. A quantitative modeling study by Roux et al. [49] also suggested that the inhibition of proteasome significantly affected cFLIP concentration and death signal sensitivity in an isoform-specific manner. As most substrate proteins require prior polyubiquitylation to be degraded by proteasome, cFLIP polyubiquitylation is thought to play critical roles in regulating cell fate. However, the E3 ubiquitin ligases responsible for the polyubiquitylation of cFLIP may not be a single one. Rather, it appears that various E3 ubiquitin ligases recognize and polyubiquitylate cFLIP in an isoform-, cell type-, context-, or signal-dependent manner. Here, we summarize the examples of these E3 ubiquitin ligases for cFLIP and discuss their physiological relevance (Table 1).
Table
Table 1. Candidate E3 ubiquitin ligases for cFLIP polyubiquitylation.
Table 1. Candidate E3 ubiquitin ligases for cFLIP polyubiquitylation.
E3 ubiquitin LigaseTypeSubstrateReferences
ItchHECTcFLIPL[50,51,52,53,54,55,56,57,58,59,60]
CblRINGcFLIPS[50,61]
Cbl-bRINGcFLIPL[62]
Mind bomb1RINGcFLIPL[51]
TRAF7RINGcFLIPL[52]
CHIPU-boxcFLIPL[53]

3.3. Itch as an E3 Ubiquitin Ligase for cFLIP Polyubiquitylation

Chang et al. [54] identified that Itch, an E3 ubiquitin ligase also known as AIP4, was required for cFLIPL degradation in a Jun N-terminal kinase 1 (JNK1)-dependent manner during TNF-α-dependent cell death. We previously reported that cFLIPL directly bound to MAP kinase kinase 7 (MKK7) and inhibited JNK pathway [55], and that the downregulation of cFLIP induced JNK activation and the accumulation of reactive oxygen species in tumor cells [56]. Therefore, the mutual regulation between cFLIP and JNK-Itch pathway might be critically important to determine the destiny of cells. Murata et al. [57] reported that the interaction between cFLIPL and Itch was blocked in Trypanosoma cruzi-infected HeLa cells, suggesting that the inhibition of cFLIPL degradation was the parasite’s survival strategy to prevent host cell apoptosis. Demange et al. [58] reported that TG interacting factor (TGIF), a homeodomain protein, promoted TNF-α-dependent apoptosis by increasing the accessibility between cFLIPL and Itch. Panner et al. [59,60] reported that Itch itself was ubiquitylated in an Akt-dependent manner in glioblastoma multiform. The inhibition of Itch ubiquitylation, either by the depletion of PTEN or by the overexpression of ubiquitin-specific protease 8 (USP8), also led to cFLIPS ubiquitylation. Similarly, Haimerl et al. [63] reported that the TNF-α-mediated downregulation of USP2, another ubiquitin-specific protease for polyubiquitylated Itch, stabilized both cFLIPL and cFLIPS in hepatocytes.
Itch is also reported to be regulated by p53 tumor suppressor protein. Abedini et al. [64,65] found that cisplatin treatment induced the formation of Itch-p53-cFLIP complex and subsequent cFLIP polyubiquitylation. The same group recently showed that gelsolin, a regulator protein of actin dynamics, was also involved in the regulation of Itch-p53-cFLIP and conferred chemoresistance against cisplatin in gynecologic cancers [66]. It was also shown that ataxia telangiectasia mutated (ATM), a protein kinase required for DNA damage checkpoint, activated Itch through Ser161 phosphorylation and induced cFLIPL degradation [67]. These results indicate that cFLIP is regulated not only by TNF-α-mediated extrinsic signal pathway, but also by DNA damage-induced intrinsic signal pathway. In addition, cystatin B, an endogenous inhibitor protein of lysosomal cathepsins, reduced the amount of Itch and increased the level of cFLIPL in melanoma cells [68].
However, several studies have identified Itch-independent polyubiquitylation of cFLIP isoforms. Shi et al. [69] reported that the TNF-α-induced degradation of cFLIPL in macrophages was mediated by PI3 kinase-Akt signaling pathway but independent of JNK-Itch. Sánchez-Pérez et al. [70,71] found that mitotic arrest-induced proteasomal degradation of cFLIP by microtubule-interfering agents was independent of Itch and sensitized cells to TRAIL-induced apoptosis in breast cancer cells. Moreover, Yerbes and Lόpez-Rivas also reported that a histone deacetylase inhibitor suberoylanilide hydroxamic acid induced the Itch-independent proteasomal degradation of both cFLIPL and cFLIPS and sensitized breast tumor cells to TRAIL [72]. These results clearly indicate that Itch is not the sole E3 ubiquitin ligase responsible for cFLIP polyubiquitylation.

3.4. Other Candidate E3 Ubiquitin Ligases for cFLIP Polyubiquitylation

Other E3 ubiquitin ligases were also identified in different cellular contexts. Kundu et al. [50] observed Cbl-dependent polyubiquitylation and proteasomal degradation of cFLIPs during Mycobacterium tuberculosis-induced apoptosis of macrophages. Zhao et al. [61] also showed that Cbl-dependent degradation of cFLIPS was accelerated by the inhibition of mTOR complex 2 in non-small cell lung carcinoma cells. In contrast, Zhang et al. [62] showed that Cbl-b was involved in the arsenic trioxide-induced degradation of cFLIPL in leukemic and gastric cancer cells. Moreover, Zhang and Gallaghar reported that Mind bomb 1, a multi-domain E3 ubiquitin ligase involved in Notch signaling, induced cFLIPL degradation when overexpressed in 293T and HeLa cells [51]. Scudiero et al. [52] reported that TNF receptor-associated factor 7 (TRAF7), another E3 ubiquitin ligase, induced Lys29-, Lys33-, Lys48, and Lys63-linked polyubiquitylation of cFLIPL. Interestingly, unconventional Lys29-linked polyubiquitylation promoted lysosomal degradation of cFLIPL in addition to proteasome-mediated degradation. Wang et al. [53] reported that C-terminus of HSP70-interacting protein (CHIP), another E3 ubiquitin ligase, was involved in the downregulation of cFLIPL induced by HSP90 inhibition in lung cancer cells.

3.5. Post-Translational Modifications Regulating cFLIP Stability

A number of studies have indicated that the stability of cFLIP is regulated by phosphorylation, and some researchers have identified the phosphorylation sites and responsible kinases. Kaunisto et al. [73] found that Ser193, present in all cFLIP isoforms, was phosphorylated by protein kinase C. They showed that phospho-mimetic mutation of Ser193Asp prolonged the half-lives of cFLIPS and cFLIPR but not cFLIPL. Wilkie-Grantham et al. [74] reported the generation of reactive oxygen species induced the phosphorylation of cFLIPL at Thr166, which was required for the subsequent polyubiquitylation at Lys167. In addition, S-nitrosylation was also reported to affect the stability of cFLIP. Chanvorachote et al. [75] found that the generation of nitric oxide induced S-nitrosylation of cFLIPL at Cys254 and Cys259, which inhibited the polyubiquitylation of cFLIPL and protected cells from CD95-induced apoptosis. cFLIP stability might be regulated by other types of post-translational modifications, including acetylation, methylation or oxidation. Further genetic and proteomic approaches will reveal more information concerning the post-translational modifications of cFLIP.

3.6. Physiological Significance of cFLIP Polyubiquitylation

One may wonder why cFLIP can be ubiquitylated by so many E3 ubiquitin ligases. One possibility is that the cellular level of cFLIP is strictly regulated by both constitutive and signal-dependent pathways in a different manner. As discussed in the above section, the cellular level of cFLIP is a critical determinant of cell survival and death in the extrinsic apoptosis pathway. Therefore, the level of cFLIP may be differentially regulated between cell death-sensitive and cell death-resistant cells. Another important point is the intrinsic instability of cFLIP proteins. Endogenous cFLIP was reported to be downregulated by heat stress or “hyperthermia”, suggesting that cFLIP is prone to denaturation or aggregation [76,77,78,79]. Indeed, Ishioka et al. [80] reported that the overexpressed cFLIPL formed aggregates in the cells and impaired the normal activity of the ubiquitin-proteasome system. Hence, we should be cautious in interpreting the results of cFLIP degradation from cellular overexpression experiments. It is necessary to discriminate whether the experimentally observed cFLIP polyubiquitylation is a physiologically regulated phenomenon, or is simply a response against misfolded proteins such as Lys63-linked polyubiquitylation for aggresome targeting [81].

4. Physiological Roles of cFLIP in Maintaining Tissue Homeostasis in Mammals

4.1. Embryonic Lethality of Cflip-Deficient Mice

Gene targeting in mice is one of the most effective ways to analyze the physiological functions of the gene of interest in mammals. However, the initial experiment revealed that the mice embryos lacking all isoforms of cFLIP from whole body, generated by disrupting the exon 1 of Cflar gene, could not survive beyond E10.5 [82]. Shibata et al. [83], very recently reported the Cflip-l+46 mutant mice, which expressed cFLIPL with C-terminal 46-amino acid extension due to a mutation at the stop codon (X482W). As this cFLIPL mutant protein was polyubiquitylated by TRIM21 E3 ubiquitin ligase and rapidly degraded by proteasome, these mice also died at around E13.5. These results clearly showed the importance of cFLIP during normal mammalian development, but also prevented us from investigating the physiological functions of cFLIP in adult animals. Since then, various researchers including us have employed special techniques or strategies to overcome this embryonic lethal problem. Here, we briefly summarize the experimental results using double- and triple-knockout mice, tissue-specific conditional knockout mice, and isoform-specific transgenic mice (Table 2).
Table
Table 2. Phenotypes of cFLIP gene-manipulated mice.
Table 2. Phenotypes of cFLIP gene-manipulated mice.
Genotype/OrganPhenotypeReferences
Whole body KO miceCflip−/−Embryonic lethality[82]
Cflip-l+46 mutantEmbryonic lethality[83]
Cflip−/−Ripk3−/−Embryonic lethality[84]
Cflip−/−Fadd−/−Ripk3−/−Normal development[84]
Conditional KO miceT cellsIncreased cell death[85,86,87,88]
B cellsIncreased cell death[89,90]
Myeloid lineageGrowth retardation, Splenomegaly[91,92]
Dendritic cellsIncreased inflammation[93,94]
LiverIncreased liver failure[95,96,97,98,99,100]
IntestineIncreased cell death and inflammation[95,101]
Skin epidermisIncreased cell death and inflammation[102,103]
Transgenic micecFLIPR in Cflip-deficient T cellsSimilar to Cflip-deficient T cells[104,105]
cFLIPL in T cellsIncreased survival[106,107,108,109,110,111,112,113,114,115]
cFLIPS in T cellsIncreased survival[116,117]
cFLIPL in neuronIncreased survival[118]
cFLIPL in thyroidBetter resolution from autoimmune disease[119,120,121,122]
cFLIPL in heartReduced cardiac hypertrophy, prevention of cardiac remodeling[123,124,125]
cFLIPL in eosinophilIncreased survival[126]
cFLIPL in testisTestis atrophy[127]
cFLIPL in muscleMuscle aging[128]
cFLIPR in hematopoietic cellsBetter bacterial clearance, increased autoimmune disease[129,130]

4.2. Rescue of Cflip-Deficient Mice by Ablating Apoptosis and Necroptosis

Caspase-8 is the principal initiator caspase, and FADD is the essential adaptor protein for the death receptor-mediated extrinsic apoptosis pathway. Both Casp8-deficient and Fadd-deficient mice are embryonic lethal, indicating their indispensable survival functions for normal development. Oberst et al. [131] reported that the embryonic lethal phenotype of Casp8-deficent mice was rescued by the additional deletion of Ripk3, a central player of necroptosis, although these mice displayed a progressive lympho-accumulative disease. They further showed that the catalytically active caspase-8-cFLIPL complex prevented RIPK3-dependent necroptosis without inducing apoptosis. Subsequently, the same group showed that both Fadd−/−Ripk3−/− double knockout mice and Cflip−/−Fadd−/−Ripk3−/− triple knockout mice were viable in a similar manner to Casp8−/−Ripk3−/− double knockout mice. However, the embryonic lethal phenotype of Cflip-deficient mice was not rescued by the additional deletion of Ripk3 alone. These results suggest that, in the presence of RIPK3, the active caspase-8-cFLIPL complex is necessary to prevent RIPK3-dependent necroptosis. In contrast, when RIPK3 is absent, cFLIP plays essential roles in blocking caspase-8- and FADD-dependent extrinsic apoptosis pathway [84,102]. Therefore, cFLIPL is required for the inhibition of both apoptosis and necroptosis to maintain the normal development and survival of mice.

4.3. Conditional Knockout Mice Lacking cFLIP in T Cells

Chau et al. [85] analyzed Cflip-deficient T cells from chimeric mice generated by reconstituting Rag1−/− blastocysts with Cflip-deficient embryonic stem cells. They found that Cflip-deficient T cells were defective in T cell receptor (TCR)-stimulated proliferation and cell survival, but TCR-induced ERK activation was not affected. Zhang and He generated Cflip-floxed mice in which exon 1 of Cflar gene was flanked by two loxP sites (described as CflipF/F hereafter). They crossed CflipF/F mice with the transgenic mice expressing Cre under Lck promoter to generate mice lacking Cflip only in T cells. These mice showed severely impaired T cell maturation at the single positive thymocyte stage due to increased apoptosis, although NF-κB and ERK signaling remained intact [86]. The same group showed that cFLIP also protected mature T cell from not only death receptor-mediated extrinsic apoptosis, but also from death induced by TCR engagement [87]. As an alternative approach, Cflip deletion was induced by tamoxifen administration in CflipF/F mice expressing ERT2-Cre under Rosa26 promoter. Using this system, He et al. [88] isolated mature T cells from these mice and deleted Cflip from these cells by the addition of tamoxifen in vitro. They found that Cflip protected resting mature T cells not only from extrinsic apoptosis pathway, but also from staurosporine-induced intrinsic apoptosis pathway.

4.4. Conditional Knockout Mice Lacking cFLIP in Other Lineages of Blood Cells

The physiological roles of cFLIP in B cells were also investigated by the expression of Cre under Cd19 promoter in CflipF/F mice. Zhang et al. [89] reported that Cflip-deficient B cells developed normally but were hypersensitive to Fas-induced apoptosis and resistant to Toll-like receptors (TLRs)- and B-cell receptor (BCR)-induced proliferation. Although NF-κB and ERK signaling was unaffected, p38 and JNK were aberrantly activated in Cflip-deficient B cells. Moreover, Coffey and Manser found that the Cflip-deficient B cells showed reduced recruitment into germinal center response [90].
Gordy et al. [91] expressed Cre under Lyz2 promoter in CflipF/F background to generate mice lacking cFLIP in myeloid lineage. Huang et al. [92] independently generated Cflip-floxed mice in which exons 2-3 of Cflar gene were flanked by loxP sequences, and they also generated myeloid-specific Cflip-deficient mice using the same strategy. These mice displayed an increase of circulating neutrophils and exhibited splenomegaly, which was due to the failure of macrophage differentiation and subsequent defective clearance of apoptotic neutrophils.
Huang et al. [93] also expressed Cre under Itgax promoter to delete Cflip specifically in dendritic cells (DCs). These mice developed spontaneous inflammatory arthritis, with an increase in autoreactive CD4+ T cells and the reduction of T regulatory cells. Very recently, Wu et al. [94] independently found that Cflip-deficient DCs generated by the same strategy displayed enhanced production of inflammatory cytokines upon innate signaling in a caspase-8 independent manner. These results indicated the unexpected suppressive roles of Cflip against innate immunity and inflammation signaling.

4.5. Conditional Knockout Mice Lacking cFLIP in Liver

Liver is the indispensable multi-functional organ for metabolic regulations, detoxifications, and the control of systemic homeostasis. Therefore, it is of great interest to determine whether Cflip is involved in the maintenance of healthy liver. Contrary to our expectation, liver-specific Cflip-deleted mice generated by the expression of Cre under Alb promoter (Alb-Cre) in CflipF/F background were apparently healthy. However, this was due to the incomplete deletion of Cflip by Alb-Cre system, as we also reported that the complete ablation of Cflip in liver in mice expressing Cre using Afp enhancer-Alb promoter (Alfp-Cre) resulted in perinatal lethality [95]. Therefore, the mice generated with Alb-Cre system should be regarded as “Cflip-hypomorphic” rather than “Cflip-deficient”. Nevertheless, this animal model is useful to study the roles of Cflip under pathological conditions of adult liver. We and others reported that the reduction of Cflip increased the susceptibility of liver cells against various insults including anti-CD95 antibody, d-galactosamine and lipopolysaccharide, and concanavalin A [95,96]. Moreover, Cflip reduction resulted in the increased severity of acute liver injury and fibrosis induced by multiple chemical drugs, including carbon tetrachloride, thioacetamide, menadione, and streptozotocin [96,97,98,99]. In a different experimental setting, we crossed CflipF/F mice with interferon-inducible Mx1-Cre transgenic mice, in which expression of Cre is induced in hepatocytes as well as hematopoietic cells after the administration of poly I:C. These mice also developed fatal hepatitis after poly I:C administration, thereby confirming the protecting role of Cflip in liver [95].
To achieve the systemic ubiquitous deletion of Cflip in adult mice, Gehrke et al. [110] expressed ERT2-Cre under Rosa26 promoter in CflipF/F mice. In these mice, intraperitoneal injection of tamoxifen resulted in the deletion of Cflip in multiple organs including liver, spleen and intestine, and these mice died within a few days after tamoxifen administration because of acute liver failure. This lethality was rescued by the transplantation of normal bone marrow or the depletion of macrophages, and the authors suggested that the observed acute liver failure was due to the activation of innate immune receptors.

4.6. Conditional Knockout Mice Lacking cFLIP in Epithelial Cells

Epithelial cells of intestine and skin are important barriers that protect animals from pathogenic organisms and toxic chemical compounds. We found that intestinal epithelium-specific deletion of Cflip generated by the expression Cre under Vil1 promoter in CflipF/F mice resulted in perinatal lethality [95]. Cell death by both apoptosis and necroptosis were already observed in intestinal epithelial cells (IEC) in utero, indicating that the observed defects were due to enhanced apoptosis of IEC rather than by pathogenic bacterial infection. Interestingly, additional deletion of Tnfrsf1a rescued the perinatal lethality of IEC-specific Cflip-deficient mice. These results were confirmed by Wittkopf et al. [101], who also showed that the acute ablation of Cflip in IEC of adult mice, generated by the tamoxifen treatment of CflipF/F mice expressing ERT2-Cre under Vil1 promoter, caused excessive apoptosis and gut inflammation.
For the specific deletion of Cflip in the epidermis, Weinlich et al. [102] locally administrated tamoxifen in the skin of CflipF/F mice expressing ERT2-Cre in the whole body under Rosa26 promoter. Panayotova-Dimitrova et al. [103] first generated epidermis-specific Cflip-deficient mice by expressing Cre under Krt14 promoter. As these mice were embryonic lethal, the researchers then expressed ERT2-Cre instead of Cre, and carried out a similar experiment to delete Cflip by local tamoxifen treatment in skin. Both groups showed that Cflip-deleted skin displayed a severe inflammation and TNF-α-mediated caspase activation, which was rescued by antagonizing TNF-α. Importantly, this phenotype was not rescued by the additional Ripk3 deletion [102], and necroptosis was not observed in Cflip-deficient skin [103]. These results suggest that the main function of Cflip in the epidermis is to prevent TNF-α-dependent apoptosis.

4.7. cFLIP Isoform-Specific Transgenic Mice

The original floxed allele established by Zhang and He targeted the exon 1 of Cflar gene shared by both cFLIPL and cFLIPR (please remind that cFLIPS is absent in mice). Therefore, Cre-mediated recombination resulted in the deletion of both cFLIPL and cFLIPR. To identify the isoform-specific roles of cFLIP, BAC transgene-mediated expression of cFLIPR into Cflip-deficient mice resulted in the generation of mice lacking only cFLIPL, thereby enabling the investigation of isoform-specific roles of cFLIP. T cells from mice lacking only cFLIPL exhibited defective TCR-mediated proliferation and severely impaired effector T cell development after Listeria monocytogenes infection in vivo, although NF-κB activation was normal [104]. In addition, cFLIPL-deficient T cells underwent both apoptosis and RIPK1-mediated necroptosis upon TCR stimulation. Moreover, these cells also exhibited enhanced autophagy as a cytoprotective response [105].
As described in the previous section, it is somewhat controversial whether the physiological functions of cFLIP isoforms are similar or distinct. To clarify these issues, several isoform-specific transgenic mice were generated and analyzed, especially in T cells. Lens et al. [106] generated transgenic mice overexpressing cFLIPL in T cells under Hbb promoter-human CD2 enhancer. Tai et al. [107] used both Cd2 and Lck promoter to express cFLIPL in T cells. In contrast, Oehme et al. [116] generated transgenic mice expressing human cFLIPS in T cells under Lck promoter. These transgenic T cells were all resistant to CD95-induced apoptosis, whereas activation-induced cell death was not affected. In this condition, mouse cFLIPL and human cFLIPS appeared to play similar roles. Increased activation of caspase-8 and NF-κB was observed in cFLIPL-transgenic CD8+ T cells, presumably due to increased caspase-8-cFLIPL heterodimer formation. The authors suggested that a sub-lethal level of caspase-8 activity was required for T cell activation [108,109]. Wu et al. [110] reported that T-cell specific cFLIPL-transgenic mice produced reduced amount of IFN-γ and increased amounts of Th2 cytokines, and displayed Th2-driven enhanced sensitivity to OVA-induced asthma. Tseveleki et al. [111] reported that transgenic mice expressing human cFLIPL in T cells under human CD2 promoter showed augmented Th2 responses, and were resistant to Th1-driven experimental autoimmune encephalomyelitis. However, upon Leishmania major infection, these mice were able to overcome this Th2 bias and mounted a robust Th1 response to clear infection [112].
In a different situation, the roles of cFLIPL and cFLIPS were completely opposite. The increased T cell signaling in cFLIPL transgenic mice reduced the severity of myocarditis induced by Coxsackievirus B3 (CVB3) infection [113]. In contrast, human cFLIPS transgenic mice were highly sensitive to CVB3 infection and manifested increased severity of myocarditis [117]. However, disease pathologies may depend on multiple factors including genetic background, as T cell-specific cFLIPL expression caused lupus-like syndrome in BALB/C but not in C57BL/6 strain [114].
In addition to T cells, several other tissues and organs were examined for the effect of cFLIP transgenic overexpression. In neurons, knockdown of cFLIPL enhanced cell death induced by glucose-deprivation, whereas transgenic mice expressing cFLIPL under Nefl promoter showed reduced lesion volume after permanent middle cerebral artery occlusion [118]. In thyroid epithelial cells, expression of cFLIPL under rat Tg promoter protected cells from Fas-mediated apoptosis [119], and these transgenic mice were apparently healthy [120]. When granulomatous experimental autoimmune thyroiditis (G-EAT) was experimentally induced by the intravenous injection of mouse thyroglobulin, thyroid epithelial cell-specific cFLIPL transgenic mice displayed better resolution of G-EAT, although disease severity were different between DBA/1 and CBA/J mice [121,122]. When G-EAT was induced in mice expressing cFLIPL in T and B cells under Hbb promoter-human CD2 enhancer to use as donor mice, these mice unexpectedly transferred less severe G-EAT to recipient mice due to reduced autoantibody production [115]. Moreover, heart-specific human cFLIPL expression under Myh6 promoter prevented cardiac remodeling induced by angiotensin II [123] and myocardial infarction [124]. Recently, Gordy et al. [125] used various tissue- and isoform-specific Cflip-deficient and transgenic mice to find that only cFLIPL was necessary for mouse eosinophil survival in the presence of TNF-α both in vitro and in vivo. Collectively, these data suggest that cFLIPL overexpression can prevent various tissues from pathological damages.
However, transgene-mediated overexpression of cFLIP isoforms may not always maintain homeostasis of tissue, organ, and whole body. When cFLIPL was overexpressed selectively in testis under Stra8 promoter [132], the male mice showed testis atrophy and reduced sperm motility [126]. This promoter also unexpectedly induced cFLIPL overexpression in heart and skeletal muscle. Overexpression of cFLIPL in heart reduced cardiac hypertrophy in response to pressure overload [127]. However, cFLIPL overexpression in skeletal muscle resulted in muscle aging due to enhanced proliferation and concomitant apoptosis of muscle satellite cells [128]. Telieps et al. [129] generated transgenic mice expressing cFLIPR specifically in hematopoietic cells under Vav1 promoter. When challenged with Listeria monocytogenes, cFLIPR transgenic mice showed better bacterial clearance than wild type mice, but developed a systemic lupus erythematosus-like autoimmunity with age [130]. These results infer that too much cell survival may be harmful to maintaining tissue homeostasis, and that the concentration and balance of cFLIP isoforms are critical determinants.
Mice do not express cFLIPS, whereas a single SNP determines whether CFLAR gene produces cFLIPS or cFLIPR in humans [13]. This may raise a question whether the absence of cFLIPS in mice has any biological significance. The data from transgenic mice studies suggest that human cFLIPS can functionally replace mouse cFLIPR. However, the extensive biochemical analysis revealed different biochemical properties between cFLIPS and cFLIPR [12]. Moreover, cFLIPR expression was associated with lymphoma risk [13] and triptolide chemosensitivity [133]. Therefore, when expressed under natural promoter, cFLIPS and cFLIPR may cause different outcomes not observed in transgenic studies.

5. Conclusions

As we summarize in this review, cFLIP is a critical switch to control cell survival and death in various tissues. Most notably in TNF-α-mediated signaling pathway, cFLIP regulates both extrinsic apoptosis pathway and necroptosis pathway. From the clinical view, apoptosis induction is expected to be an effective way to kill tumor cells for cancer treatment. Indeed, a number of studies have indicated that the overexpression of cFLIP in various types of cancer cells may confer resistance against anti-cancer drugs [134]. In addition, blocking TNF-α signaling is a promising therapeutic strategy against several inflammatory diseases mediated by TNF-α. For example, TNF-neutralizing antibodies are approved and widely used for the treatment of various inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease [135]. Therefore, cFLIP has been regarded as an attractive target molecule to treat cancer and inflammation diseases. However, recent studies from gene-manipulated mice have also revealed the essential role of cFLIP in maintaining homeostasis in various tissues. Therefore, simple whole-body inhibition of cFLIP may cause unexpected side effects and reduce quality of life. As all cFLIP isoforms are intracellular proteins, antibody-mediated targeting of cFLIP may not be applicable. Therefore, therapeutic strategies may include the development of chemical compounds that modulate the function and stability of cFLIP. Moreover, numerous cellular studies have identified several drugs and chemical agents that inhibit the transcription of cFLIP, although their specificities remain to be evaluated. Further studies will be necessary for the complete understanding of cFLIP function and for the development of cFLIP-mediated therapeutic strategies without side effects.

Acknowledgments

We apologize to the authors whose original papers could not be cited due to space limitation. This work was supported by MEXT/JSPS KAKENHI (Grant numbers 24390100, 25670167, and 26110003), and grants from the Takeda Science Foundation, the Uehara Memorial Foundation, and the Naito Foundation to HN. YT and ON were also supported by Project Research Grant 26-3 and 26-31, respectively, from Toho University School of Medicine.

Author Contributions

Yuichi Tsuchiya, Osamu Nakabayashi and Hiroyasu Nakano wrote and edited the review.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Galluzzi, L.; Bravo-San Pedro, J.M.; Vitale, I.; Aaronson, S.A.; Abrams, J.M.; Adam, D.; Alnemri, E.S.; Altucci, L.; Andrews, D.; Annicchiarico-Petruzzelli, M.; et al. Essential versus accessory aspects of cell death: Recommendations of the NCCD 2015. Cell Death Differ. 2015, 22, 58–73. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Thome, M.; Schneider, P.; Hofmann, K.; Fickenscher, H.; Meinl, E.; Neipel, F.; Mattmann, C.; Burns, K.; Bodmer, J.L.; Schröter, M.; et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997, 386, 517–521. [Google Scholar] [CrossRef] [PubMed]
  3. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J.L.; Schröter, M.; Burns, K.; Mattmann, C.; et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388, 190–195. [Google Scholar] [PubMed]
  4. Shu, H.B.; Halpin, D.; Goeddel, D.V. Casper is a FADD- and caspase-related inducer of apoptosis. Immunity 1997, 6, 751–763. [Google Scholar] [CrossRef]
  5. Hu, S.; Vincenz, C.; Ni, J.; Gentz, R.; Dixit, V.M. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J. Biol. Chem. 1997, 272, 17255–17257. [Google Scholar] [CrossRef] [PubMed]
  6. Srinivasula, S.M.; Ahmad, M.; Ottilie, S.; Bullrich, F.; Banks, S.; Wang, Y.; Fernandes-Alnemri, T.; Croce, C.M.; Litwack, G.; Tomaselli, K.J.; et al. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J. Biol. Chem. 1997, 272, 18542–18545. [Google Scholar] [CrossRef] [PubMed]
  7. Goltsev, Y.V.; Kovalenko, A.V.; Arnold, E.; Varfolomeev, E.E.; Brodianskii, V.M.; Wallach, D. CASH, a novel caspase homologue with death effector domains. J. Biol. Chem. 1997, 272, 19641–19644. [Google Scholar] [CrossRef] [PubMed]
  8. Inohara, N.; Koseki, T.; Hu, Y.; Chen, S.; Núñez, G. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc. Natl. Acad. Sci. USA 1997, 94, 10717–10722. [Google Scholar] [CrossRef] [PubMed]
  9. Han, D.K.; Chaudhary, P.M.; Wright, M.E.; Friedman, C.; Trask, B.J.; Riedel, R.T.; Baskin, D.G.; Schwartz, S.M.; Hood, L. MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death. Proc. Natl. Acad. Sci. USA 1997, 94, 11333–11338. [Google Scholar] [CrossRef] [PubMed]
  10. Rasper, D.M.; Vaillancourt, J.P.; Hadano, S.; Houtzager, V.M.; Seiden, I.; Keen, S.L.; Tawa, P.; Xanthoudakis, S.; Nasir, J.; Martindale, D.; et al. Cell death attenuation by “Usurpin”, a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ. 1998, 5, 271–288. [Google Scholar] [CrossRef] [PubMed]
  11. Golks, A.; Brenner, D.; Fritsch, C.; Krammer, P.H.; Lavrik, I.N. c-FLIPR, a new regulator of death receptor-induced apoptosis. J. Biol. Chem. 2005, 280, 14507–14513. [Google Scholar] [CrossRef] [PubMed]
  12. Ueffing, N.; Keil, E.; Freund, C.; Kühne, R.; Schulze-Osthoff, K.; Schmitz, I. Mutational analyses of c-FLIPR, the only murine short FLIP isoform, reveal requirements for DISC recruitment. Cell Death Differ. 2008, 15, 773–782. [Google Scholar] [CrossRef] [PubMed]
  13. Ueffing, N.; Singh, K.K.; Christians, A.; Thorns, C.; Feller, A.C.; Nagl, F.; Fend, F.; Heikaus, S.; Marx, A.; Zotz, R.B.; et al. A single nucleotide polymorphism determines protein isoform production of the human c-FLIP protein. Blood 2009, 114, 572–579. [Google Scholar] [CrossRef] [PubMed]
  14. Salvesen, G.S.; Walsh, C.M. Functions of caspase 8: The identified and the mysterious. Semin. Immunol. 2014, 26, 246–252. [Google Scholar] [CrossRef] [PubMed]
  15. Nakano, H.; Piao, X.; Shindo, R.; Komazawa-Sakon, S. Cellular FLICE-Inhibitory protein regulates tissue homeostasis. Curr. Top. Microbiol. Immunol. 2015. [Google Scholar] [CrossRef]
  16. Safa, A.R. Roles of c-FLIP in apoptosis, necroptosis, and autophagy. J. Carcinog. Mutagen. 2013, 6. [Google Scholar] [CrossRef] [PubMed]
  17. Krueger, A.; Schmitz, I.; Baumann, S.; Krammer, P.H.; Kirchhoff, S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 2001, 276, 20633–20640. [Google Scholar] [CrossRef] [PubMed]
  18. Chang, D.W.; Xing, Z.; Pan, Y.; Algeciras-Schimnich, A.; Barnhart, B.C.; Yaish-Ohad, S.; Peter, M.E.; Yang, X. c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 2002, 21, 3704–3714. [Google Scholar] [CrossRef] [PubMed]
  19. Micheau, O.; Thome, M.; Schneider, P.; Holler, N.; Tschopp, J.; Nicholson, D.W.; Briand, C.; Grütter, M.G. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J. Biol. Chem. 2002, 277, 45162–45171. [Google Scholar] [CrossRef] [PubMed]
  20. Boatright, K.M.; Deis, C.; Denault, J.B.; Sutherlin, D.P.; Salvesen, G.S. Activation of caspases-8 and -10 by FLIPL. Biochem. J. 2004, 382, 651–657. [Google Scholar] [CrossRef] [PubMed]
  21. Pop, C.; Oberst, A.; Drag, M.; van Raam, B.J.; Riedl, S.J.; Green, D.R.; Salvesen, G.S. FLIPL induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity. Biochem. J. 2011, 433, 447–457. [Google Scholar] [CrossRef] [PubMed]
  22. Yu, J.W.; Jeffrey, P.D.; Shi, Y. Mechanism of procaspase-8 activation by c-FLIPL. Proc. Natl. Acad. Sci. USA 2009, 106, 8169–8174. [Google Scholar] [CrossRef] [PubMed]
  23. Dickens, L.S.; Boyd, R.S.; Jukes-Jones, R.; Hughes, M.A.; Robinson, G.L.; Fairall, L.; Schwabe, J.W.; Cain, K.; Macfarlane, M. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol. Cell 2012, 47, 291–305. [Google Scholar] [CrossRef] [PubMed]
  24. Schleich, K.; Warnken, U.; Fricker, N.; Oztürk, S.; Richter, P.; Kammerer, K.; Schnölzer, M.; Krammer, P.H.; Lavrik, I.N. Stoichiometry of the CD95 death-inducing signaling complex: Experimental and modeling evidence for a death effector domain chain model. Mol. Cell 2012, 47, 306–319. [Google Scholar] [CrossRef] [PubMed]
  25. Siegel, R.M.; Martin, D.A.; Zheng, L.; Ng, S.Y.; Bertin, J.; Cohen, J.; Lenardo, M.J. Death-effector filaments: Novel cytoplasmic structures that recruit caspases and trigger apoptosis. J. Cell Biol. 1998, 141, 1243–1253. [Google Scholar] [CrossRef] [PubMed]
  26. Majkut, J.; Sgobba, M.; Holohan, C.; Crawford, N.; Logan, A.E.; Kerr, E.; Higgins, C.A.; Redmond, K.L.; Riley, J.S.; Stasik, I.; et al. Differential affinity of FLIP and procaspase 8 for FADD’s DED binding surfaces regulates DISC assembly. Nat. Commun. 2014, 5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Kallenberger, S.M.; Beaudouin, J.; Claus, J.; Fischer, C.; Sorger, P.K.; Legewie, S.; Eils, R. Intra- and interdimeric caspase-8 self-cleavage controls strength and timing of CD95-induced apoptosis. Sci. Signal. 2014, 7, ra23. [Google Scholar] [CrossRef] [PubMed]
  28. Schleich, K.; Buchbinder, J.H.; Pietkiewicz, S.; Kähne, T.; Warnken, U.; Öztürk, S.; Schnölzer, M.; Naumann, M.; Krammer, P.H.; Lavrik, I.N. Molecular architecture of the DED chains at the DISC: Regulation of procaspase-8 activation by short DED proteins c-FLIP and procaspase-8 prodomain. Cell Death Differ. 2015. [Google Scholar] [CrossRef] [PubMed]
  29. Varfolomeev, E.E.; Boldin, M.P.; Goncharov, T.M.; Wallach, D. A potential mechanism of “cross-talk” between the p55 tumor necrosis factor receptor and Fas/APO1: Proteins binding to the death domains of the two receptors also bind to each other. J. Exp. Med. 1996, 183, 1271–1275. [Google Scholar] [CrossRef] [PubMed]
  30. Hsu, H.; Huang, J.; Shu, H.-B.; Baichwal, V.; Goeddel, D.V. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-a signaling complex. Immunity 1996, 4, 387–396. [Google Scholar] [CrossRef]
  31. Weinlich, R.; Green, D.R. The two faces of receptor interacting protein kinase-1. Mol. Cell 2014, 56, 469–480. [Google Scholar] [CrossRef] [PubMed]
  32. Tenev, T.; Bianchi, K.; Darding, M.; Broemer, M.; Langlais, C.; Wallberg, F.; Zachariou, A.; Lopez, J.; MacFarlane, M.; Cain, K.; et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol. Cell 2011, 43, 432–448. [Google Scholar] [CrossRef] [PubMed]
  33. Feoktistova, M.; Geserick, P.; Kellert, B.; Dimitrova, D.P.; Langlais, C.; Hupe, M.; Cain, K.; MacFarlane, M.; Häcker, G.; Leverkus, M. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol. Cell 2011, 43, 449–463. [Google Scholar] [CrossRef] [PubMed]
  34. Schilling, R.; Geserick, P.; Leverkus, M. Characterization of the ripoptosome and its components: Implications for anti-inflammatory and cancer therapy. Methods Enzymol. 2014, 545, 83–102. [Google Scholar] [PubMed]
  35. Pasparakis, M.; Vandenabeele, P. Necroptosis and its role in inflammation. Nature 2015, 517, 311–320. [Google Scholar] [CrossRef] [PubMed]
  36. He, S.; Wang, L.; Miao, L.; Wang, T.; Du, F.; Zhao, L.; Wang, X. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-α. Cell 2009, 137, 1100–1111. [Google Scholar] [CrossRef] [PubMed]
  37. Feoktistova, M.; Geserick, P.; Panayotova-Dimitrova, D.; Leverkus, M. Pick your poison: The ripoptosome, a cell death platform regulating apoptosis and necroptosis. Cell Cycle 2012, 11, 460–467. [Google Scholar] [CrossRef] [PubMed]
  38. Mandal, P.; Berger, S.B.; Pillay, S.; Moriwaki, K.; Huang, C.; Guo, H.; Lich, J.D.; Finger, J.; Kasparcova, V.; Votta, B.; et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol. Cell 2014, 56, 481–495. [Google Scholar] [CrossRef] [PubMed]
  39. Day, T.W.; Huang, S.; Safa, A.R. c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8, and caspase-9-dependent apoptosis in breast cancer cells. Biochem. Pharmacol. 2008, 76, 1694–1704. [Google Scholar] [CrossRef] [PubMed]
  40. Estornes, Y.; Toscano, F.; Virard, F.; Jacquemin, G.; Pierrot, A.; Vanbervliet, B.; Bonnin, M.; Lalaoui, N.; Mercier-Gouy, P.; Pachéco, Y.; et al. dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. Cell Death Differ. 2012, 19, 1482–1494. [Google Scholar] [CrossRef] [PubMed]
  41. Bentele, M.; Lavrik, I.; Ulrich, M.; Stösser, S.; Heermann, D.W.; Kalthoff, H.; Krammer, P.H.; Eils, R. Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis. J. Cell Biol. 2004, 166, 839–851. [Google Scholar] [CrossRef] [PubMed]
  42. Lavrik, I.N.; Golks, A.; Riess, D.; Bentele, M.; Eils, R.; Krammer, P.H. Analysis of CD95 threshold signaling: Triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J. Biol. Chem. 2007, 282, 13664–13671. [Google Scholar] [CrossRef] [PubMed]
  43. Lavrik, I.N. Systems biology of death receptor networks: Live and let die. Cell Death Dis. 2014, 5, e1259. [Google Scholar] [CrossRef] [PubMed]
  44. Fricker, N.; Beaudouin, J.; Richter, P.; Eils, R.; Krammer, P.H.; Lavrik, I.N. Model-based dissection of CD95 signaling dynamics reveals both a pro- and antiapoptotic role of c-FLIPL. J. Cell Biol. 2010, 190, 377–389. [Google Scholar] [CrossRef] [PubMed]
  45. Han, L.; Zhao, Y.; Jia, X. Mathematical modeling identified c-FLIP as an apoptotic switch in death receptor induced apoptosis. Apoptosis 2008, 13, 1198–1204. [Google Scholar] [CrossRef] [PubMed]
  46. Neumann, L.; Pforr, C.; Beaudouin, J.; Pappa, A.; Fricker, N.; Krammer, P.H.; Lavrik, I.N.; Eils, R. Dynamics within the CD95 death-inducing signaling complex decide life and death of cells. Mol. Syst. Biol. 2010, 6, 352. [Google Scholar] [CrossRef] [PubMed]
  47. Scaffidi, C.; Schmitz, I.; Krammer, P.H.; Peter, M.E. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 1999, 274, 1541–1548. [Google Scholar] [CrossRef] [PubMed]
  48. Toivonen, H.T.; Meinander, A.; Asaoka, T.; Westerlund, M.; Pettersson, F.; Mikhailov, A.; Eriksson, J.E.; Saxén, H. Modeling reveals that dynamic regulation of c-FLIP levels determines cell-to-cell distribution of CD95-mediated apoptosis. J. Biol. Chem. 2011, 286, 18375–18382. [Google Scholar] [CrossRef] [PubMed]
  49. Roux, J.; Hafner, M.; Bandara, S.; Sims, J.J.; Hudson, H.; Chai, D.; Sorger, P.K. Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold. Mol. Syst. Biol. 2015, 11, 803. [Google Scholar] [CrossRef] [PubMed]
  50. Kundu, M.; Pathak, S.K.; Kumawat, K.; Basu, S.; Chatterjee, G.; Pathak, S.; Noguchi, T.; Takeda, K.; Ichijo, H.; Thien, C.B.; et al. A TNF- and c-Cbl-dependent FLIPS-degradation pathway and its function in Mycobacterium tuberculosis-induced macrophage apoptosis. Nat. Immunol. 2009, 10, 918–926. [Google Scholar] [CrossRef] [PubMed]
  51. Zhang, L.; Gallagher, P.J. Mind bomb 1 regulation of cFLIP interactions. Am. J. Physiol. Cell Physiol. 2009, 297, C1275–C1283. [Google Scholar] [CrossRef] [PubMed]
  52. Scudiero, I.; Zotti, T.; Ferravante, A.; Vessichelli, M.; Reale, C.; Masone, M.C.; Leonardi, A.; Vito, P.; Stilo, R. Tumor necrosis factor (TNF) receptor-associated factor 7 is required for TNFα-induced Jun NH2-terminal kinase activation and promotes cell death by regulating polyubiquitination and lysosomal degradation of c-FLIP protein. J. Biol. Chem. 2012, 287, 6053–6061. [Google Scholar] [CrossRef] [PubMed]
  53. Wang, Q.; Sun, W.; Hao, X.; Li, T.; Su, L.; Liu, X. Down-regulation of cellular FLICE-inhibitory protein (Long Form) contributes to apoptosis induced by Hsp90 inhibition in human lung cancer cells. Cancer Cell Int. 2012, 12, 54. [Google Scholar] [CrossRef] [PubMed]
  54. Chang, L.; Kamata, H.; Solinas, G.; Luo, J.L.; Maeda, S.; Venuprasad, K.; Liu, Y.C.; Karin, M. The E3 ubiquitin ligase itch couples JNK activation to TNFα-induced cell death by inducing c-FLIPL turnover. Cell 2006, 124, 601–613. [Google Scholar] [CrossRef] [PubMed]
  55. Nakajima, A.; Komazawa-Sakon, S.; Takekawa, M.; Sasazuki, T.; Yeh, W.C.; Yagita, H.; Okumura, K.; Nakano, H. An antiapoptotic protein, c-FLIPL, directly binds to MKK7 and inhibits the JNK pathway. EMBO J. 2006, 25, 5549–5559. [Google Scholar] [CrossRef] [PubMed]
  56. Nakajima, A.; Kojima, Y.; Nakayama, M.; Yagita, H.; Okumura, K.; Nakano, H. Downregulation of c-FLIP promotes caspase-dependent JNK activation and reactive oxygen species accumulation in tumor cells. Oncogene 2008, 27, 76–84. [Google Scholar] [CrossRef] [PubMed]
  57. Murata, E.; Hashimoto, M.; Aoki, T. Interaction between cFLIP and Itch, a ubiquitin ligase, is obstructed in Trypanosoma. cruzi-infected human cells. Microbiol. Immunol. 2008, 52, 539–543. [Google Scholar] [CrossRef] [PubMed]
  58. Demange, C.; Ferrand, N.; Prunier, C.; Bourgeade, M.F.; Atfi, A. A model of partnership co-opted by the homeodomain protein TGIF and the Itch/AIP4 ubiquitin ligase for effective execution of TNF-α cytotoxicity. Mol. Cell 2009, 36, 1073–1085. [Google Scholar] [CrossRef] [PubMed]
  59. Panner, A.; Crane, C.A.; Weng, C.; Feletti, A.; Parsa, A.T.; Pieper, R.O. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res. 2009, 69, 7911–7916. [Google Scholar] [CrossRef] [PubMed]
  60. Panner, A.; Crane, C.A.; Weng, C.; Feletti, A.; Fang, S.; Parsa, A.T.; Pieper, R.O. Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res. 2010, 70, 5046–5053. [Google Scholar] [CrossRef] [PubMed]
  61. Zhao, L.; Yue, P.; Khuri, F.R.; Sun, S.Y. mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis. Cancer Res. 2013, 73, 1946–1957. [Google Scholar] [CrossRef] [PubMed]
  62. Zhang, G.; Liu, J.; Zhang, Y.; Qu, J.; Xu, L.; Zheng, H.; Liu, Y.; Qu, X. Cbl-b-dependent degradation of FLIPL is involved in ATO-induced autophagy in leukemic K562 and gastric cancer cells. FEBS Lett. 2012, 586, 3104–3110. [Google Scholar] [CrossRef] [PubMed]
  63. Haimerl, F.; Erhardt, A.; Sass, G.; Tiegs, G. Down-regulation of the de-ubiquitinating enzyme ubiquitin-specific protease 2 contributes to tumor necrosis factor-α-induced hepatocyte survival. J. Biol. Chem. 2009, 284, 495–504. [Google Scholar] [CrossRef] [PubMed]
  64. Abedini, M.R.; Muller, E.J.; Brun, J.; Bergeron, R.; Gray, D.A.; Tsang, B.K. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res. 2008, 68, 4511–4517. [Google Scholar] [CrossRef] [PubMed]
  65. Abedini, M.R.; Muller, E.J.; Bergeron, R.; Gray, D.A.; Tsang, B.K. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene 2010, 29, 11–25. [Google Scholar] [CrossRef] [PubMed]
  66. Abedini, M.R.; Wang, P.W.; Huang, Y.F.; Cao, M.; Chou, C.Y.; Shieh, D.B.; Tsang, B.K. Cell fate regulation by gelsolin in human gynecologic cancers. Proc. Natl. Acad. Sci. USA 2014, 111, 14442–14447. [Google Scholar] [CrossRef] [PubMed]
  67. Santini, S.; Stagni, V.; Giambruno, R.; Fianco, G.; Di Benedetto, A.; Mottolese, M.; Pellegrini, M.; Barilà, D. ATM kinase activity modulates ITCH E3-ubiquitin ligase activity. Oncogene 2014, 33, 1113–1123. [Google Scholar] [CrossRef] [PubMed]
  68. Yang, F.; Tay, K.H.; Dong, L.; Thorne, R.F.; Jiang, C.C.; Yang, E.; Tseng, H.Y.; Liu, H.; Christopherson, R.; Hersey, P.; et al. Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIPL from degradation by the E3 ligase itch in human melanoma cells. Cell Death Differ. 2010, 17, 1354–1367. [Google Scholar] [CrossRef] [PubMed]
  69. Shi, B.; Tran, T.; Sobkoviak, R.; Pope, R.M. Activation-induced degradation of FLIPL is mediated via the phosphatidylinositol 3-kinase/Akt signaling pathway in macrophages. J. Biol. Chem. 2009, 284, 14513–14523. [Google Scholar] [CrossRef] [PubMed]
  70. Sánchez-Pérez, T.; Ortiz-Ferrón, G.; López-Rivas, A. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents. Cell Death Differ. 2010, 17, 883–894. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  71. Sánchez-Pérez, T.; Medema, R.H.; López-Rivas, A. Delaying mitotic exit downregulates FLIP expression and strongly sensitizes tumor cells to TRAIL. Oncogene 2015, 34, 661–669. [Google Scholar] [CrossRef] [PubMed]
  72. Yerbes, R.; López-Rivas, A. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL. Investig. New Drugs 2012, 30, 541–547. [Google Scholar] [CrossRef] [PubMed]
  73. Kaunisto, A.; Kochin, V.; Asaoka, T.; Mikhailov, A.; Poukkula, M.; Meinander, A.; Eriksson, J.E. PKC-mediated phosphorylation regulates c-FLIP ubiquitylation and stability. Cell Death Differ. 2009, 13, 1215–1226. [Google Scholar] [CrossRef] [PubMed]
  74. Wilkie-Grantham, R.P.; Matsuzawa, S.; Reed, J.C. Novel phosphorylation and ubiquitination sites regulates reactive oxygen species-dependent degradation of anti-apoptotic c-FLIP protein. J. Biol. Chem. 2013, 288, 12777–12790. [Google Scholar] [CrossRef] [PubMed]
  75. Chanvorachote, P.; Nimmannit, U.; Wang, L.; Stehlik, C.; Lu, B.; Azad, N.; Rojanasakul, Y. Nitric oxide negatively regulates Fas CD95-induced apoptosis through inhibition of ubiquitin-proteasome-mediated degradation of FLICE inhibitory protein. J. Biol. Chem. 2005, 280, 42044–42050. [Google Scholar] [CrossRef] [PubMed]
  76. Tran, S.E.; Meinander, A.; Holmström, T.H.; Rivero-Müller, A.; Heiskanen, K.M.; Linnau, E.K.; Courtney, M.J.; Mosser, D.D.; Sistonen, L.; Eriksson, J.E. Heat stress downregulates FLIP and sensitizes cells to Fas receptor-mediated apoptosis. Cell Death Differ. 2003, 10, 1137–1147. [Google Scholar] [CrossRef] [PubMed]
  77. Meinander, A.; Söderström, T.S.; Kaunisto, A.; Poukkula, M.; Sistonen, L.; Eriksson, J.E. Fever-like hyperthermia controls T Lymphocyte persistence by inducing degradation of cellular FLIPshort. J. Immunol. 2007, 178, 3944–3953. [Google Scholar] [CrossRef] [PubMed]
  78. Song, X.; Kim, S.Y.; Zhou, Z.; Lagasse, E.; Kwon, Y.T.; Lee, Y.J. Hyperthermia enhances mapatumumab-induced apoptotic death through ubiquitin-mediated degradation of cellular FLIP(long) in human colon cancer cells. Cell Death Dis. 2013, 4, e577. [Google Scholar] [CrossRef] [PubMed]
  79. Morlé, A.; Garrido, C.; Micheau, O. Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion. Cell Death Dis. 2015, 6, e1633. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  80. Ishioka, T.; Katayama, R.; Kikuchi, R.; Nishimoto, M.; Takada, S.; Takada, R.; Matsuzawa, S.; Reed, J.C.; Tsuruo, T.; Naito, M. Impairment of the ubiquitin-proteasome system by cellular FLIP. Genes Cells 2007, 12, 735–744. [Google Scholar] [CrossRef] [PubMed]
  81. Brüning, A.; Jückstock, J. Misfolded proteins: From little villains to little helpers in the fight against cancer. Front. Oncol. 2015, 5, 47. [Google Scholar] [PubMed]
  82. Yeh, W.C.; Itie, A.; Elia, A.J.; Ng, M.; Shu, H.B.; Wakeham, A.; Mirtsos, C.; Suzuki, N.; Bonnard, M.; Goeddel, D.V.; et al. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 2000, 12, 633–642. [Google Scholar] [CrossRef]
  83. Shibata, N.; Ohoka, N.; Sugaki, Y.; Onodera, C.; Inoue, M.; Sakuraba, Y.; Takakura, D.; Hashii, N.; Kawasaki, N.; Gondo, Y.; et al. Degradation of stop codon read-through mutant proteins via the ubiquitin-proteasome system causes hereditary disorders. J. Biol. Chem. 2015, 190, 28428–28437. [Google Scholar] [CrossRef] [PubMed]
  84. Dillon, C.P.; Oberst, A.; Weinlich, R.; Janke, L.J.; Kang, T.B.; Ben-Moshe, T.; Mak, T.W.; Wallach, D.; Green, D.R. Survival function of the FADD-CASPASE-8-cFLIPL complex. Cell Rep. 2012, 1, 401–407. [Google Scholar] [CrossRef] [PubMed]
  85. Chau, H.; Wong, V.; Chen, N.J.; Huang, H.L.; Lin, W.J.; Mirtsos, C.; Elford, A.R.; Bonnard, M.; Wakeham, A.; You-Ten, A.I.; et al. Cellular FLICE-inhibitory protein is required for T cell survival and cycling. J. Exp. Med. 2005, 202, 405–413. [Google Scholar] [CrossRef] [PubMed]
  86. Zhang, N.; He, Y.W. An essential role for c-FLIP in the efficient development of mature T lymphocytes. J. Exp. Med. 2005, 202, 395–404. [Google Scholar] [CrossRef] [PubMed]
  87. Zhang, N.; Hopkins, K.; He, Y.W. c-FLIP protects mature T lymphocytes from TCR-mediated killing. J. Immunol. 2008, 181, 5368–5373. [Google Scholar] [CrossRef]
  88. He, M.X.; He, Y.W. c-FLIP protects T lymphocytes from apoptosis in the intrinsic pathway. J. Immunol. 2015, 194, 3444–3451. [Google Scholar] [CrossRef] [PubMed]
  89. Zhang, H.; Rosenberg, S.; Coffey, F.J.; He, Y.W.; Manser, T.; Hardy, R.R.; Zhang, J. A role for cFLIP in B cell proliferation and stress MAPK regulation. J. Immunol. 2009, 182, 207–215. [Google Scholar] [CrossRef] [PubMed]
  90. Coffey, F.; Manser, T. Expression of cellular FLIP by B cells is required for their participation in an immune response. J. Immunol. 2010, 184, 4871–4879. [Google Scholar] [CrossRef] [PubMed]
  91. Gordy, C.; Pua, H.; Sempowski, G.D.; He, Y.W. Regulation of steady-state neutrophil homeostasis by macrophages. Blood 2011, 117, 618–629. [Google Scholar] [CrossRef] [PubMed]
  92. Huang, Q.Q.; Perlman, H.; Huang, Z.; Birkett, R.; Kan, L.; Agrawal, H.; Misharin, A.; Gurbuxani, S.; Crispino, J.D.; Pope, R.M. FLIP: A novel regulator of macrophage differentiation and granulocyte homeostasis. Blood 2010, 116, 4968–4977. [Google Scholar] [CrossRef] [PubMed]
  93. Huang, Q.Q.; Perlman, H.; Birkett, R.; Doyle, R.; Fang, D.; Haines, G.K.; Robinson, W.; Datta, S.; Huang, Z.; Li, Q.Z.; et al. CD11c-mediated deletion of Flip promotes autoreactivity and inflammatory arthritis. Nat. Commun. 2015, 6, 7086. [Google Scholar] [CrossRef] [PubMed]
  94. Wu, Y.J.; Wu, Y.H.; Mo, S.T.; Hsiao, H.W.; He, Y.W.; Lai, M.Z. Cellular FLIP inhibits myeloid cell activation by suppressing selective innate signaling. J. Immunol. 2015, 195, 2612–2623. [Google Scholar] [CrossRef] [PubMed]
  95. Piao, X.; Komazawa-Sakon, S.; Nishina, T.; Koike, M.; Piao, J.H.; Ehlken, H.; Kurihara, H.; Hara, M.; van Rooijen, N.; Schütz, G.; et al. c-FLIP maintains tissue homeostasis by preventing apoptosis and programmed necrosis. Sci. Signal. 2012, 5, ra93. [Google Scholar] [CrossRef] [PubMed]
  96. Schattenberg, J.M.; Zimmermann, T.; Wörns, M.; Sprinzl, M.F.; Kreft, A.; Kohl, T.; Nagel, M.; Siebler, J.; Schulze Bergkamen, H.; He, Y.W.; et al. Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo. J. Hepatol. 2011, 55, 1272–1280. [Google Scholar] [CrossRef] [PubMed]
  97. Schattenberg, J.M.; Nagel, M.; Kim, Y.O.; Kohl, T.; Wörns, M.A.; Zimmermann, T.; Schad, A.; Longerich, T.; Schuppan, D.; He, Y.W.; et al. Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303, G498–G506. [Google Scholar] [CrossRef] [PubMed]
  98. Schattenberg, J.M.; Wörns, M.A.; Zimmermann, T.; He, Y.W.; Galle, P.R.; Schuchmann, M. The role of death effector domain-containing proteins in acute oxidative cell injury in hepatocytes. Free Radic. Biol. Med. 2012, 52, 1911–1917. [Google Scholar] [CrossRef] [PubMed]
  99. Kohl, T.; Gehrke, N.; Schad, A.; Nagel, M.; Wörns, M.A.; Sprinzl, M.F.; Zimmermann, T.; He, Y.W.; Galle, P.R.; Schuchmann, M.; et al. Diabetic liver injury from streptozotocin is regulated through the caspase-8 homolog cFLIP involving activation of JNK2 and intrahepatic immunocompetent cells. Cell Death Dis. 2013, 4, e712. [Google Scholar] [CrossRef] [PubMed]
  100. Gehrke, N.; Garcia-Bardon, D.; Mann, A.; Schad, A.; Alt, Y.; Wörns, M.A.; Sprinzl, M.F.; Zimmermann, T.; Menke, J.; Engstler, A.J.; et al. Acute organ failure following the loss of anti-apoptotic cellular FLICE-inhibitory protein involves activation of innate immune receptors. Cell Death Differ. 2015, 22, 826–837. [Google Scholar] [CrossRef] [PubMed]
  101. Wittkopf, N.; Günther, C.; Martini, E.; He, G.; Amann, K.; He, Y.W.; Schuchmann, M.; Neurath, M.F.; Becker, C. Cellular FLICE-like inhibitory protein secures intestinal epithelial cell survival and immune homeostasis by regulating caspase-8. Gastroenterology 2013, 145, 1369–1379. [Google Scholar] [CrossRef] [PubMed]
  102. Weinlich, R.; Oberst, A.; Dillon, C.P.; Janke, L.J.; Milasta, S.; Lukens, J.R.; Rodriguez, D.A.; Gurung, P.; Savage, C.; Kanneganti, T.D.; et al. Protective roles for caspase-8 and cFLIP in adult homeostasis. Cell Rep. 2013, 5, 340–348. [Google Scholar] [CrossRef] [PubMed]
  103. Panayotova-Dimitrova, D.; Feoktistova, M.; Ploesser, M.; Kellert, B.; Hupe, M.; Horn, S.; Makarov, R.; Jensen, F.; Porubsky, S.; Schmieder, A.; et al. cFLIP regulates skin homeostasis and protects against TNF-induced keratinocyte apoptosis. Cell Rep. 2013, 5, 397–408. [Google Scholar] [CrossRef] [PubMed]
  104. Zhang, N.; Hopkins, K.; He, Y.W. The long isoform of cellular FLIP is essential for T lymphocyte proliferation through an NF-κB-independent pathway. J. Immunol. 2008, 180, 5506–5511. [Google Scholar] [CrossRef] [PubMed]
  105. He, M.X.; He, Y.W. A role for c-FLIPL in the regulation of apoptosis, autophagy, and necroptosis in T lymphocytes. Cell Death Differ. 2013, 20, 188–197. [Google Scholar] [CrossRef] [PubMed]
  106. Lens, S.M.; Kataoka, T.; Fortner, K.A.; Tinel, A.; Ferrero, I.; MacDonald, R.H.; Hahne, M.; Beermann, F.; Attinger, A.; Orbea, H.A.; et al. The caspase 8 inhibitor c-FLIPL modulates T-cell receptor-induced proliferation but not activation-induced cell death of lymphocytes. Mol. Cell. Biol. 2002, 22, 5419–5433. [Google Scholar] [CrossRef] [PubMed]
  107. Tai, T.S.; Fang, L.W.; Lai, M.Z. c-FLICE inhibitory protein expression inhibits T-cell activation. Cell. Death Differ. 2004, 11, 69–79. [Google Scholar] [CrossRef] [PubMed]
  108. Dohrman, A.; Kataoka, T.; Cuenin, S.; Russell, J.Q.; Tschopp, J.; Budd, R.C. Cellular FLIP (long form) regulates CD8+ T cell activation through caspase-8-dependent NF-κB activation. J. Immunol. 2005, 174, 5270–5278. [Google Scholar] [CrossRef] [PubMed]
  109. Dohrman, A.; Russell, J.Q.; Cuenin, S.; Fortner, K.; Tschopp, J.; Budd, R.C. Cellular FLIP long form augments caspase activity and death of T cells through heterodimerization with and activation of caspase-8. J. Immunol. 2005, 175, 311–318. [Google Scholar] [CrossRef] [PubMed]
  110. Wu, W.; Rinaldi, L.; Fortner, K.A.; Russell, J.Q.; Tschopp, J.; Irvin, C.; Budd, R.C. Cellular FLIP long form-transgenic mice manifest a Th2 cytokine bias and enhanced allergic airway inflammation. J. Immunol. 2004, 172, 4724–4732. [Google Scholar] [CrossRef] [PubMed]
  111. Tseveleki, V.; Bauer, J.; Taoufik, E.; Ruan, C.; Leondiadis, L.; Haralambous, S.; Lassmann, H.; Probert, L. Cellular FLIP (long isoform) overexpression in T cells drives Th2 effector responses and promotes immunoregulation in experimental autoimmune encephalomyelitis. J. Immunol. 2004, 173, 6619–6626. [Google Scholar] [CrossRef] [PubMed]
  112. Tseveleki, V.; Tsagozis, P.; Koutsoni, O.; Dotsika, E.; Probert, L. Cellular FLIP long isoform transgenic mice overcome inherent Th2-biased immune responses to efficiently resolve Leishmania. major infection. Int. Immunol. 2007, 19, 1183–1189. [Google Scholar] [CrossRef] [PubMed]
  113. Huber, S.; Dohrman, A.; Sartini, D.; Budd, R.C. Reduced myocarditis following Coxsackievirus infection in cellular FLICE inhibitory protein—Long form-transgenic mice. Immunology 2006, 119, 541–550. [Google Scholar] [CrossRef] [PubMed]
  114. Qiao, G.; Li, Z.; Minto, A.W.; Shia, J.; Yang, L.; Bao, L.; Tschopp, J.; Gao, J.X.; Wang, J.; Quigg, R.J.; et al. Altered thymic selection by overexpressing cellular FLICE inhibitory protein in T cells causes lupus-like syndrome in a BALB/c but not C57BL/6 strain. Cell Death Differ. 2010, 17, 522–533. [Google Scholar] [CrossRef] [PubMed]
  115. Fang, Y.; Sharp, G.C.; Braley-Mullen, H. Effect of transgenic overexpression of FLIP on lymphocytes on development and resolution of experimental autoimmune thyroiditis. Am. J. Pathol. 2011, 179, 1211–1220. [Google Scholar] [CrossRef] [PubMed]
  116. Oehme, I.; Neumann, F.; Bösser, S.; Zörnig, M. Transgenic overexpression of the Caspase-8 inhibitor FLIPshort leads to impaired T cell proliferation and an increased memory T cell pool after Staphylococcal enterotoxin B injection. Eur. J. Immunol. 2005, 35, 1240–1249. [Google Scholar] [CrossRef] [PubMed]
  117. Buskiewicz, I.A.; Koenig, A.; Roberts, B.; Russell, J.; Shi, C.; Lee, S.H.; Jung, J.U.; Huber, S.A.; Budd, R.C. c-FLIP-Short reduces type I interferon production and increases viremia with coxsackievirus B3. PLoS ONE 2014, 9, e96156. [Google Scholar] [CrossRef] [PubMed]
  118. Taoufik, E.; Valable, S.; Müller, G.J.; Roberts, M.L.; Divoux, D.; Tinel, A.; Voulgari-Kokota, A.; Tseveleki, V.; Altruda, F.; Lassmann, H.; et al. FLIPL protects neurons against in vivo ischemia and in vitro glucose deprivation-induced cell death. J. Neurosci. 2007, 27, 6633–6646. [Google Scholar] [CrossRef] [PubMed]
  119. Fang, Y.; Braley-Mullen, H. Cultured murine thyroid epithelial cells expressing transgenic Fas-associated death domain-like interleukin-1β converting enzyme inhibitory protein are protected from Fas-mediated apoptosis. Endocrinology 2008, 149, 3321–3329. [Google Scholar] [CrossRef] [PubMed]
  120. Wang, S.H.; Arscott, P.; Wu, P.; Baker, J.R., Jr. No apparent damage in the thyroid of transgenic mice expressing antiapoptotic FLIP. Thyroid 2006, 16, 1–8. [Google Scholar] [CrossRef] [PubMed]
  121. Fang, Y.; Wei, Y.; Demarco, V.; Chen, K.; Sharp, G.C.; Braley-Mullen, H. Murine FLIP transgene expressed on thyroid epithelial cells promotes resolution of granulomatous experimental autoimmune thyroiditis in DBA/1 mice. Am. J. Pathol. 2007, 170, 875–887. [Google Scholar] [CrossRef] [PubMed]
  122. Fang, Y.; DeMarco, V.G.; Sharp, G.C.; Braley-Mullen, H. Expression of transgenic FLIP on thyroid epithelial cells inhibits induction and promotes resolution of granulomatous experimental autoimmune thyroiditis in CBA/J mice. Endocrinology 2007, 148, 5734–5745. [Google Scholar] [CrossRef] [PubMed]
  123. Li, H.; Tang, Q.Z.; Liu, C.; Moon, M.; Chen, M.; Yan, L.; Bian, Z.Y.; Zhang, Y.; Wang, A.B.; Nghiem, M.P.; et al. Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice. Hypertension 2010, 56, 1109–1117. [Google Scholar] [CrossRef] [PubMed]
  124. Xiao, J.; Moon, M.; Yan, L.; Nian, M.; Zhang, Y.; Liu, C.; Lu, J.; Guan, H.; Chen, M.; Jiang, D.; et al. Cellular FLICE-inhibitory protein protects against cardiac remodelling after myocardial infarction. Basic Res. Cardiol. 2012, 107, 239. [Google Scholar] [CrossRef] [PubMed]
  125. Gordy, C.; Liang, J.; Pua, H.; He, Y.W. c-FLIP protects eosinophils from TNF-α-mediated cell death in vivo. PLoS ONE 2014, 9, e107724. [Google Scholar] [CrossRef] [PubMed]
  126. Antonangeli, F.; Petrungaro, S.; Coluccia, P.; Filippini, A.; Ziparo, E.; Giampietri, C. Testis atrophy and reduced sperm motility in transgenic mice overexpressing c-FLIPL. Fertil. Steril. 2010, 93, 1407–1414. [Google Scholar] [CrossRef] [PubMed]
  127. Giampietri, C.; Petrungaro, S.; Musumeci, M.; Coluccia, P.; Antonangeli, F.; De Cesaris, P.; Filippini, A.; Marano, G.; Ziparo, E. c-Flip overexpression reduces cardiac hypertrophy in response to pressure overload. J. Hypertens. 2008, 26, 1008–1016. [Google Scholar] [CrossRef] [PubMed]
  128. Giampietri, C.; Petrungaro, S.; Coluccia, P.; Antonangeli, F.; Giannakakis, K.; Faraggiana, T.; Filippini, A.; Cossu, G.; Ziparo, E. c-Flip overexpression affects satellite cell proliferation and promotes skeletal muscle aging. Cell Death Dis. 2010, 1, e38. [Google Scholar] [CrossRef] [PubMed]
  129. Telieps, T.; Ewald, F.; Gereke, M.; Annemann, M.; Rauter, Y.; Schuster, M.; Ueffing, N.; von Smolinski, D.; Gruber, A.D.; Bruder, D.; et al. Cellular-FLIP, Raji isoform (c-FLIPR) modulates cell death induction upon T-cell activation and infection. Eur. J. Immunol. 2013, 43, 1499–1510. [Google Scholar] [CrossRef] [PubMed]
  130. Ewald, F.; Annemann, M.; Pils, M.C.; Plaza-Sirvent, C.; Neff, F.; Erck, C.; Reinhold, D.; Schmitz, I. Constitutive expression of murine c-FLIPR causes autoimmunity in aged mice. Cell Death Dis. 2014, 5, e1168. [Google Scholar] [CrossRef] [PubMed]
  131. Oberst, A.; Dillon, C.P.; Weinlich, R.; McCormick, L.L.; Fitzgerald, P.; Pop, C.; Hakem, R.; Salvesen, G.S.; Green, D.R. Catalytic activity of the caspase-8-FLIPL complex inhibits RIPK3-dependent necrosis. Nature 2011, 471, 363–367. [Google Scholar] [CrossRef] [PubMed]
  132. Antonangeli, F.; Giampietri, C.; Petrungaro, S.; Filippini, A.; Ziparo, E. Expression profile of a 400-bp Stra8 promoter region during spermatogenesis. Microsc. Res. Tech. 2009, 72, 816–822. [Google Scholar] [CrossRef] [PubMed]
  133. Chauhan, L.; Jenkins, G.D.; Bhise, N.; Feldberg, T.; Mitra-Ghosh, T.; Fridley, B.L.; Lamba, J.K. Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity. BMC Genom. 2015, 16, 483. [Google Scholar] [CrossRef] [PubMed]
  134. Safa, A.R.; Pollok, K.E. Targeting the Anti-apoptotic protein c-FLIP for cancer therapy. Cancers 2011, 2, 1639–1671. [Google Scholar] [CrossRef] [PubMed]
  135. Urbano, P.C.; Soccol, V.T.; Azevedo, V.F. Apoptosis and the FLIP and NF-κB proteins as pharmacodynamic criteria for biosimilar TNF-α antagonists. Biologics 2014, 8, 211–220. [Google Scholar] [PubMed]

Share and Cite

MDPI and ACS Style

Tsuchiya, Y.; Nakabayashi, O.; Nakano, H. FLIP the Switch: Regulation of Apoptosis and Necroptosis by cFLIP. Int. J. Mol. Sci. 2015, 16, 30321-30341. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms161226232

AMA Style

Tsuchiya Y, Nakabayashi O, Nakano H. FLIP the Switch: Regulation of Apoptosis and Necroptosis by cFLIP. International Journal of Molecular Sciences. 2015; 16(12):30321-30341. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms161226232

Chicago/Turabian Style

Tsuchiya, Yuichi, Osamu Nakabayashi, and Hiroyasu Nakano. 2015. "FLIP the Switch: Regulation of Apoptosis and Necroptosis by cFLIP" International Journal of Molecular Sciences 16, no. 12: 30321-30341. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms161226232

Article Metrics

Back to TopTop